Status:
COMPLETED
Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
Detailed Description
Schizophrenia is a chronic and severe brain disorder that can significantly impact quality of life. It is characterized by delusions, paranoia, and disordered thinking. The cause of schizophrenia has ...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia
Exclusion
- History of cardiovascular illness or neurological illness other than schizophrenia
- Current substance abuse, including nicotine
- History of clozapine use
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00255918
Start Date
March 1 2004
End Date
October 1 2005
Last Update
July 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado General Clinical Research Center
Denver, Colorado, United States, 80262